-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Eosinophilic esophagitis (EoE) is a chronic, immune- mediated disease.
Eosinophilic esophagitis (EoE) is a chronic, immune- mediated disease.
In this double-blind, placebo-controlled trial, patients with EoE between the ages of 11 and 55 and those with dysphagia were randomly assigned to receive budesonide oral suspension (BOS) 2.
In the end, a total of 318 patients participated in this study (213 in the BOS group; 105 in the placebo group).
Figure: Changes of inflammation indexes after budesonide treatment of eosinophilic esophagitis
This study confirmed that in patients with EoE, the histology, clinical symptoms and endoscopic performance of the patients can be well improved within 12 weeks after receiving budesonide oral liquid treatment.
Original source:
Ikuo Hirano .
Related Products
